Synthesis: Sacituzumab govitecan (ASCENT)

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Why sacituzumab govitecan

Triple-negative breast cancer has historically had few targeted-therapy options because the defining negative IHC results (ER−, PR−, HER2−) eliminate the three most common targets. The antibody-drug conjugate (ADC) class circumvents this by using an antibody as a homing device for a cytotoxic payload, requiring only that the antibody's target be expressed on tumor cells — not that the target be a driver oncogene.

Trop-2 (Trophoblast cell-surface antigen 2; gene TACSTD2) is a transmembrane glycoprotein expressed on the surface of most epithelial cancers including the majority of TNBC. Trop-2 is also expressed on normal epithelial tissues but at lower density, providing a therapeutic window. Bardia and colleagues estimated Trop-2 staining intensity of 2+ or 3+ on at least 80% of TNBC tumors in archival samples^[1]A, making it a plausible pan-TNBC target rather than a stratified-subgroup biomarker.

Sacituzumab govitecan (formerly IMMU-132) is a humanized anti-Trop-2 IgG1 antibody (hRS7) conjugated to SN-38 (the active metabolite of irinotecan) via a hydrolyzable CL2A linker. The construct achieves a high drug-to-antibody ratio (~7.6:1) compared with most prior ADCs (~3:1), and the linker is designed to release payload extracellularly in the tumor microenvironment in addition to internalized intracellular release — the "bystander effect" hypothesis^[2]B.

Pre-ASCENT phase II evidence and accelerated approval

A phase I/II single-arm trial in 108 heavily pre-treated metastatic TNBC patients (Bardia 2019)^[1] showed an objective response rate of 33.3% (95% CI 24.6–43.1%) with a median duration of response of 7.7 months — substantially higher than the 5–15% ORR typical of single-agent chemotherapy in this setting. The FDA granted sacituzumab accelerated approval for metastatic TNBC after at least two prior systemic therapies in April 2020 based on this single-arm data, contingent on confirmatory phase III results.

ASCENT — the confirmatory trial

Bardia and colleagues randomized 529 patients with metastatic TNBC who had received at least two prior chemotherapies for metastatic disease 1:1 to sacituzumab govitecan vs single-agent chemotherapy of physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine)^[3]A. Patients with treated brain metastases were eligible; patients with active brain metastases were excluded.

The primary endpoint was PFS in the subset of patients without brain metastases (n=468). The final analysis triggered early stopping by the independent data monitoring committee for efficacy.

• Primary endpoint PFS (no brain mets subset): median 5.6 vs 1.7 months, HR 0.41 (95% CI 0.32–0.52; p<0.001)
• Overall survival (no brain mets subset): median 12.1 vs 6.7 months, HR 0.48 (95% CI 0.38–0.59; p<0.001)
• Objective response rate: 35% vs 5%
• Full-trial OS (including brain mets): 11.8 vs 6.9 months, HR 0.51

The benefit was consistent across pre-specified subgroups including age, prior lines of therapy, race, and visceral disease pattern. The brain-metastasis subgroup analysis showed numerical benefit with sacituzumab (median OS 6.8 vs 7.5 months; HR 0.90) but with a small sample (n=61) and wide confidence intervals.

Regulatory consequence: the accelerated approval was converted to regular approval by the FDA in April 2021 on the strength of the ASCENT confirmatory data. EMA approved sacituzumab for the same indication in November 2021.

Toxicity profile

Sacituzumab's payload is SN-38 (the active form of irinotecan); accordingly, its toxicity profile resembles that of irinotecan more than that of a typical antibody-drug conjugate. The most common grade 3 or higher adverse events in ASCENT:

• Neutropenia: 51% (vs 33% with chemotherapy); febrile neutropenia 6%. Growth-factor support is commonly used.
• Diarrhea: 11% grade 3+ (vs less than 1% with chemo). Sometimes severe; loperamide and supportive care are first-line management.
• Anemia: 8% grade 3+
• Alopecia: common but cosmetic
• Hypersensitivity reactions: uncommon but require pre-medication per the label

The UGT1A1 *28 polymorphism (Gilbert's syndrome) increases SN-38 exposure and toxicity risk; FDA labeling notes increased neutropenia risk in *28/*28 patients but does not require routine pre-treatment genotyping^[4]B. Dose reduction is the standard management for grade 3+ toxicity rather than treatment discontinuation, with the goal of maintaining patients on therapy for as long as benefit continues.

Trop-2 expression and biomarker considerations

A pre-specified retrospective analysis of ASCENT examined whether Trop-2 IHC staining intensity predicts benefit. Patients were stratified by H-score (an integrative measure of staining intensity and percentage). Across all H-score strata, sacituzumab outperformed chemotherapy — though the magnitude of benefit was larger in high-Trop-2 patients^[5]B:

• H-score 200–300 (high): PFS 6.9 vs 2.5 months
• H-score 100–200 (moderate): PFS 5.6 vs 2.2 months
• H-score < 100 (low): PFS 2.7 vs 1.6 months

The low-Trop-2 subgroup still benefited, but the absolute PFS values were modest. Whether Trop-2 IHC should be used as a clinical biomarker for sacituzumab selection remains debated; the current FDA label does not require Trop-2 testing, and most practices do not test routinely.

Sequencing with trastuzumab deruxtecan (the dual-ADC era)

The HER2-low expansion of trastuzumab deruxtecan (see DESTINY-Breast04 synthesis) created a near-simultaneous second ADC option for the same metastatic-TNBC population. About half of historically-TNBC tumors are HER2-low (IHC 1+ or 2+/ISH−) and therefore eligible for both sacituzumab and trastuzumab deruxtecan. Optimal sequencing between the two is not established by head-to-head data; sequence is currently informed by toxicity-profile differences and patient-specific factors:

• Sacituzumab first, T-DXd second — the more common contemporary practice, partly because sacituzumab approval preceded T-DXd's HER2-low indication by ~2 years and many community practitioners have more comfort with it.
• T-DXd first, sacituzumab second — preferred when the patient has prior irinotecan/topotecan exposure (cross-resistance concern with sacituzumab's SN-38 payload), or when GI toxicity from sacituzumab is a particular concern.
• Cross-resistance. Limited prospective data on cross-resistance between the two ADCs. Retrospective series suggest some response is preserved when the second ADC is given, but with shorter duration of benefit than the first^[6]C.

In HER2-zero TNBC (IHC 0), sacituzumab remains the only ADC option until newer agents enter the landscape.

Moving sacituzumab earlier in the metastatic line

Several pivotal trials are testing sacituzumab in earlier metastatic lines and in early-stage adjuvant settings:

• ASCENT-04 (first-line metastatic, biomarker-negative). Tests sacituzumab + pembrolizumab vs investigator's-choice chemotherapy + pembrolizumab in PD-L1+ first-line metastatic TNBC. Primary readout pending.
• ASCENT-03 (first-line metastatic, PD-L1 negative). Tests sacituzumab monotherapy vs investigator's-choice chemotherapy in PD-L1 CPS < 10 first-line metastatic TNBC — specifically addressing the largest unmet-need subgroup. Primary readout pending.
• SASCIA and TROPICS-08 (early-stage adjuvant). Test adjuvant sacituzumab in residual disease after neoadjuvant therapy. Both ongoing; outcomes anticipated for late 2026 / 2027.
• ASCENT-05 (early-stage neoadjuvant). Tests sacituzumab + pembrolizumab vs pembrolizumab alone in residual disease following neoadjuvant chemo+IO. Early proof-of-concept stage.

Evidence table — sacituzumab govitecan key trials

Open questions and active investigation

• Will sacituzumab earn first-line approval? The ASCENT-03 and ASCENT-04 readouts are the most consequential next data points for the metastatic-TNBC field. Positive results would substantially restructure first-line decision trees, particularly for the biomarker-negative subgroup.
• Adjuvant role in residual disease. If SASCIA or TROPICS-08 are positive, sacituzumab joins capecitabine and olaparib as a residual-disease adjuvant option following neoadjuvant chemo+IO. The sequencing/combination question with those existing options is largely unaddressed.
• Trop-2 IHC as a clinical biomarker. Current label doesn't require it; whether quantitative Trop-2 expression should guide patient selection (especially in earlier-line trials) remains open. The DAISY-CDx and similar companion-diagnostic development efforts may eventually settle this.
• Mechanisms of acquired resistance. Trop-2 expression loss has been observed in serial biopsies of patients with acquired resistance to sacituzumab, though not universally. The competing hypothesis is acquired alterations in DNA-damage-response (since SN-38 is a topoisomerase-I inhibitor). Distinguishing these mechanisms would guide post-progression strategy.
• Datopotamab deruxtecan (Dato-DXd). A second Trop-2-targeting ADC with a different payload (DXd, the trastuzumab-deruxtecan payload) and different linker chemistry. TROPION-Breast01 in HR+/HER2− mBC was positive in 2023; TROPION-Breast02 in TNBC is reading out. Direct comparison with sacituzumab has not been done; cross-resistance and sequencing are open questions for the next 2–3 years.
• Bystander effect heterogeneity. The hydrolyzable linker that enables sacituzumab's putative bystander effect varies in efficiency across tumor microenvironments. Whether the bystander effect is meaningful for outcomes in low-Trop-2 tumors is unclear; the answer would inform patient selection.

For the trastuzumab deruxtecan companion (HER2-low metastatic), see DESTINY-Breast04 synthesis. For the first-line decision tree that determines who gets to sacituzumab as a third-line option, see First-line metastatic synthesis. For the patient-layer companion, see Treatment options.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741–751. doi:10.1056/NEJMoa1814213. ↩
2. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496–22512. doi:10.18632/oncotarget.4318. ↩
3. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (ASCENT). N Engl J Med. 2021;384(16):1529–1541. doi:10.1056/NEJMoa2028485. ↩
4. US Food and Drug Administration. Trodelvy (sacituzumab govitecan-hziy) prescribing information. Updated 2023. Accessed via fda.gov. ↩
5. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148–1156. doi:10.1016/j.annonc.2021.06.002. ↩
6. Huppert LA, Mahtani RL, O'Shaughnessy J, et al. Real-world outcomes of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024;10(1):11. doi:10.1038/s41523-024-00617-7. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.